Cardiovascular, Renal & Metabolic Disease

Cardiovascular, renal, and metabolic (CVRM) diseases, including obesity and type 2 diabetes, are a major public health emergency, impacting over half of the global population, causing 19 million deaths annually, and imposing a tremendous burden on healthcare systems and society. Despite the availability of numerous treatment options, significant gaps remain in addressing the unmet needs of patients, as many therapies have not significantly altered disease trajectories. Advances in human genetics and disease biology have recently identified new therapeutic targets, and innovative modalities such as siRNAs, ASOs, cell therapies, and gene silencing are opening doors to treatments for previously untreatable conditions. 

Roche is uniquely positioned to address these challenges with its comprehensive pipeline of potential best- and first-in-class investigational medicines, Diagnostics and Digital Solutions aimed at improving outcomes, reducing societal burdens, and transforming care for patients with CVRM diseases throughout their journey. We are highly committed to contributing to areas of highest unmet need and societal burden through transformative science, expanding our footprint in cardiovascular and metabolic diseases.

• Uncontrolled hypertension

• Obesity  (also in context of Diabetes)

• MASH (metabolic dysfunction-associated steatohepatitis)

• Myocardial infarction/ stroke secondary prevention

• Cardiomyopathies

• SPAF (stroke & systemic embolic prevention in atrial fibrillation)